|
HLA-DRB1
|
0.180 |
Biomarker
|
group |
BEFREE |
Our findings also suggest possible interactions among HLA-DRB1*03:01 and smoking on the risk of PM and ILD, as well as, anti-synthetase, anti-Jo-1, and anti-p155/140 autoantibodies in Caucasians.
|
29703532 |
2018 |
|
HLA-DRB1
|
0.180 |
GeneticVariation
|
group |
BEFREE |
No difference in the frequency of DRB1 alleles, other than *04:01, carrying the "shared epitope" (SE), i.e., *01:01, *01:02, *04:05, and *10:01, was observed between the controls and patients with DM stratified by the presence of anti-MDA5 and ILD.
|
28711882 |
2017 |
|
HLA-DRB1
|
0.180 |
GeneticVariation
|
group |
BEFREE |
PADI4 polymorphisms and HLA-DRB1 alleles could attribute differently to the development of airway abnormalities and ILD, respectively, in RA.
|
27372294 |
2016 |
|
HLA-DRB1
|
0.180 |
Biomarker
|
group |
BEFREE |
These results suggest that the combination of HLA-B*15:01 and DRB1*15:01 is associated with ILD in Japanese patients with advanced pancreatic cancer receiving gemcitabine plus erlotinib.
|
27100735 |
2016 |
|
HLA-DRB1
|
0.180 |
Biomarker
|
group |
BEFREE |
The association between ILD and smoking is dependent on the HLA-DRB1 SE, which may reflect gene-environment interaction.
|
26255186 |
2015 |
|
HLA-DRB1
|
0.180 |
Biomarker
|
group |
BEFREE |
HLA-DRB1 SE was associated with reduced, while DR2 serological group (DRB1*15 and *16) with increased, risk for ILD in Japanese patients with RA.
|
22586441 |
2012 |
|
HLA-DRB1
|
0.180 |
GeneticVariation
|
group |
BEFREE |
The combined frequency of the DRB1*0101 allele and the DRB1*0405 allele was significantly higher in patients with anti-MDA-5 antibody-positive DM than in patients with PM/DM without anti-aaRS antibody or ILD, with an odds ratio (OR) of 42.7 (95% confidence interval [95% CI] 4.9-370.2) (P = 1.1 × 10(-5)), or in patients with anti-aaRS antibody-positive PM/DM (OR 13.3 [95% CI 1.6-112.6], P = 4.5 × 10(-3)).
|
22886382 |
2012 |
|
HLA-DRB1
|
0.180 |
Biomarker
|
group |
BEFREE |
The carriage of HLA-DRB1*1502 had opposite influences on the two conditions: relative risk ratio = 4.02 for ILD (p = 0.013) and relative risk ratio = 0.15 for AD (p = 0.08).
|
22867979 |
2012 |
|
HLA-DRB1
|
0.180 |
Biomarker
|
group |
HPO |
|
|
|